Phaseline

Targets › CD45RA

CD45RA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2031.

Open in Phaseline: the race on CD45RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital of PhiladelphiaCD45RA Depleted Stem Cell Addback (CD45RO+ T cells)
CD45RA-depleted, CD45RO+ memory T cell addback to accelerate immune reconstitution post TC
CD45RAPhase 1LeukemiaMar 2031

Conditions

Leukemia (1)

Modalities

–

Companies

Children's Hospital of Philadelphia (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.